암 생물학적 요법 시장

Global Cancer Biological Therapy Market to Reach US$173.1 Billion by 2030

The global market for Cancer Biological Therapy estimated at US$121.9 Billion in the year 2024, is expected to reach US$173.1 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$69.9 Billion by the end of the analysis period. Growth in the Cancer Growth Blockers segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$33.2 Billion While China is Forecast to Grow at 9.6% CAGR

The Cancer Biological Therapy market in the U.S. is estimated at US$33.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$35.5 Billion by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global "Cancer Biological Therapy" Market - Key Trends & Drivers Summarized

How Is Biological Therapy Transforming The Cancer Treatment Paradigm?

Cancer biological therapy represents a pivotal shift from traditional chemotherapies to more targeted and immune-based approaches, leveraging the body's natural mechanisms or engineered biological agents to combat cancer cells. These therapies include monoclonal antibodies, cytokine therapies, cancer vaccines, oncolytic viruses, and CAR-T cell therapies. Unlike cytotoxic drugs, biological therapies offer precision targeting, potentially reducing collateral damage to healthy tissues and improving patient quality of life. With rising global cancer incidence, there's a pressing need for treatments that go beyond broad-spectrum options-particularly for refractory and metastatic cancers. Biologics are proving effective across a range of malignancies including lymphomas, melanoma, breast cancer, and lung cancer. The integration of diagnostics and biomarkers into treatment decisions has enabled biological therapies to be tailored to genetic profiles, increasing their success rates. Combination therapies involving checkpoint inhibitors and monoclonals are also opening new frontiers. Moreover, immunotherapy-an important subset of biological therapy-is rapidly becoming a first-line option in many countries, signaling a fundamental evolution in oncology treatment strategy.

What Scientific Innovations Are Expanding The Therapeutic Reach Of Biologics?

The cancer biological therapy landscape is being redefined by breakthroughs in cell engineering, genetic editing, and antibody development. The advent of bispecific antibodies, which can simultaneously bind to cancer cells and T-cells, is creating potent new treatment modalities. CAR-T cell therapy, initially used in hematologic malignancies, is being adapted for solid tumors through improved tumor-targeting and persistence technologies. Personalized neoantigen vaccines are being developed to boost immune recognition of tumor-specific mutations. Synthetic biology is enabling programmable immune cells with built-in safety switches and dual-function mechanisms. CRISPR gene editing is being used to enhance the performance of adoptive cell therapies, minimizing immune escape by tumors. Additionally, advances in protein engineering are yielding antibody-drug conjugates (ADCs) that combine high specificity with powerful cytotoxic payloads. AI-driven predictive modeling is facilitating the design of biologics with optimized pharmacokinetics and minimal toxicity. These innovations are not just expanding the types of cancers that can be treated but are also enabling therapy development that is faster, more cost-effective, and more targeted than ever before.

How Are Regulatory Shifts And Patient Demands Reshaping Cancer Biologics?

The regulatory landscape for cancer biological therapies is undergoing transformation to keep pace with innovation, leading to faster approval pathways like FDA’s Breakthrough Therapy and EMA’s PRIME designations. Accelerated approvals for drugs such as checkpoint inhibitors and CAR-T therapies underscore the urgency and impact of these treatments. However, regulators are also enforcing stringent post-market surveillance and real-world evidence requirements due to the complexity and novelty of biologics. Patient advocacy has become a force in shaping treatment access, with increasing pressure on healthcare systems to subsidize or reimburse cutting-edge therapies. The rise of value-based healthcare is prompting payers to assess outcomes-based models for biologics reimbursement. In parallel, there's increasing emphasis on diversity in clinical trials, particularly for immunotherapies, which can behave differently across populations. Ethical considerations around gene-modified therapies are also leading to stricter oversight in manufacturing and consent protocols. Furthermore, the growing role of companion diagnostics in therapy selection is pushing biologics companies to partner closely with diagnostic firms to co-develop biomarker-led strategies. This holistic regulatory-patient dynamic is accelerating innovation while demanding higher transparency and safety.

The Growth In The Cancer Biological Therapy Market Is Driven By Several Factors…

…including rising cancer prevalence, increased adoption of personalized medicine, and growing investment in immuno-oncology pipelines. Demand is surging for biologics in difficult-to-treat cancers, particularly those resistant to standard chemotherapy or radiation. The success of PD-1/PD-L1 inhibitors and CAR-T cell products has spurred a wave of biotech and pharma investment in next-gen immunotherapies. Pharmaceutical giants are expanding their biological portfolios through acquisitions, while governments are funding cancer research through public-private partnerships. In developing regions, the rollout of healthcare infrastructure is increasing access to advanced therapies, supported by rising awareness and early diagnosis initiatives. Trends in consumer behavior show patients increasingly seeking therapies with fewer side effects and longer remission durations. The expansion of clinical trials globally, especially in Asia-Pacific, is facilitating the entry of biologics into new cancer subtypes and indications. Tele-oncology and digital health platforms are enhancing patient management and follow-up, supporting biologic adherence and outcomes tracking. Together, these drivers are forging a robust foundation for the continued evolution of the cancer biological therapy market.

SCOPE OF STUDY:

The report analyzes the Cancer Biological Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines, Vaccines); Administration Route (Oral Administration, Injectable Administration)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• AbbVie Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Incyte Corporation
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis International AG
• Pfizer Inc.
• Sanofi S.A.
• Seattle Genetics, Inc. (Seagen Inc.)
• Takeda Pharmaceutical Company Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Cancer Biological Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Preference for Targeted Therapies Over Conventional Chemotherapy
  • Rising Approvals and Pipeline Expansion of Monoclonal Antibody Treatments
  • Increased Investment in Immunotherapy Research Boosting Market Innovation
  • Adoption of CAR-T Cell Therapy Driving Personalized Medicine Adoption
  • Surge in Demand for Checkpoint Inhibitors Across Multiple Cancer Types
  • Advancements in Biomarker and Companion Diagnostic Technologies Supporting Targeted Therapy
  • Increasing Role of Biopharmaceutical Companies in Cancer Therapeutics Development
  • Expansion of Biosimilars and Biobetters Enhancing Market Accessibility
  • Growing Use of Combination Biological Therapies for Enhanced Efficacy
  • Rising Patient Demand for Less Invasive and More Tolerable Treatment Options
  • Rapid Uptake of Precision Oncology Creating Opportunities for Biological Agents
  • Emergence of Neoantigen-Based Therapies and Cancer Vaccines Fueling Research
  • Improved Clinical Outcomes Supporting Shift Toward Biologic-Based Cancer Care
  • Government and Private Funding in Oncology Driving Clinical Trial Acceleration
  • Increased Collaboration Between Diagnostic and Therapeutic Players Enabling Personalized Approaches
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cancer Biological Therapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cancer Biological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Cancer Biological Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Cancer Growth Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Cancer Growth Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Blood Cell Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Blood Cell Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Cytokines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Cytokines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 18: USA Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 19: USA 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 20: USA Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 21: USA 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• CANADA
  • TABLE 22: Canada Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 23: Canada 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 24: Canada Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 25: Canada 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• JAPAN
  • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 26: Japan Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Japan 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 28: Japan Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: Japan 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• CHINA
  • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 30: China Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: China 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 32: China Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: China 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• EUROPE
  • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 34: Europe Recent Past, Current & Future Analysis for Cancer Biological Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 35: Europe 6-Year Perspective for Cancer Biological Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 36: Europe Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Europe 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 38: Europe Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Europe 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• FRANCE
  • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 40: France Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: France 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 42: France Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: France 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• GERMANY
  • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 44: Germany Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Germany 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 46: Germany Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Germany 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• ITALY
  • TABLE 48: Italy Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Italy 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 50: Italy Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Italy 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• UNITED KINGDOM
  • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 52: UK Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: UK 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 54: UK Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: UK 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• SPAIN
  • TABLE 56: Spain Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Spain 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 58: Spain Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Spain 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• RUSSIA
  • TABLE 60: Russia Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Russia 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 62: Russia Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Russia 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 64: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Rest of Europe 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 66: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Rest of Europe 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• ASIA-PACIFIC
  • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biological Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: Asia-Pacific 6-Year Perspective for Cancer Biological Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
  • TABLE 70: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Asia-Pacific 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 72: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Asia-Pacific 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• AUSTRALIA
  • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 74: Australia Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Australia 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 76: Australia Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: Australia 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• INDIA
  • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 78: India Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: India 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 80: India Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: India 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• SOUTH KOREA
  • TABLE 82: South Korea Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: South Korea 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 84: South Korea Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: South Korea 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 86: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of Asia-Pacific 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 88: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Rest of Asia-Pacific 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• LATIN AMERICA
  • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 90: Latin America Recent Past, Current & Future Analysis for Cancer Biological Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 91: Latin America 6-Year Perspective for Cancer Biological Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
  • TABLE 92: Latin America Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Latin America 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 94: Latin America Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Latin America 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• ARGENTINA
  • TABLE 96: Argentina Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Argentina 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 98: Argentina Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Argentina 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• BRAZIL
  • TABLE 100: Brazil Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 101: Brazil 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 102: Brazil Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 103: Brazil 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• MEXICO
  • TABLE 104: Mexico Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Mexico 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 106: Mexico Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 107: Mexico 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 108: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 109: Rest of Latin America 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 110: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Rest of Latin America 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• MIDDLE EAST
  • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 112: Middle East Recent Past, Current & Future Analysis for Cancer Biological Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 113: Middle East 6-Year Perspective for Cancer Biological Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
  • TABLE 114: Middle East Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 115: Middle East 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 116: Middle East Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Middle East 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• IRAN
  • TABLE 118: Iran Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 119: Iran 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 120: Iran Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 121: Iran 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• ISRAEL
  • TABLE 122: Israel Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Israel 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 124: Israel Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 125: Israel 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• SAUDI ARABIA
  • TABLE 126: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 127: Saudi Arabia 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 128: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Saudi Arabia 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 130: UAE Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 131: UAE 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 132: UAE Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 133: UAE 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 134: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Middle East 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 136: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 137: Rest of Middle East 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030
• AFRICA
  • Cancer Biological Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 138: Africa Recent Past, Current & Future Analysis for Cancer Biological Therapy by Product - Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 139: Africa 6-Year Perspective for Cancer Biological Therapy by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines and Vaccines for the Years 2025 & 2030
  • TABLE 140: Africa Recent Past, Current & Future Analysis for Cancer Biological Therapy by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Africa 6-Year Perspective for Cancer Biological Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2025 & 2030

IV. COMPETITION